Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • British Medical Journal

    - PMLiVE

    Johnson & Johnson seeks first EMA approval for icotrokinra for plaque psoriasis

    Icotrokinra is a first-in-class, once-daily tablet for moderate-to-severe plaque psoriasis

    - PMLiVE

    Almirall and Absci expand AI dermatological drug discovery partnership

    The alliance has already led to the delivery of functional antibody leads against a difficult-to-drug target

    - PMLiVE

    J&J/Protagonist’s icotrokinra shows promise in difficult-to-treat plaque psoriasis

    An estimated eight million people in the US are living with the immune-mediated skin disease

    - PMLiVE

    Almirall hosts Skin Academy to advance skin science and dermatology treatments

    The conference will cover actinic keratosis, psoriasis, atopic dermatitis and other skin diseases

    - PMLiVE

    J&J/Protagonist’s icotrokinra shows promise in phase 3 plaque psoriasis programme

    More than 125 million people worldwide are estimated to be living with the immune-mediated skin disease

    - PMLiVE

    Bristol Myers Squibb shares five-year results for Sotyktu in plaque psoriasis

    Plaque psoriasis affects up to 90% of patients with the immune-mediated disease

    - PMLiVE

    J&J and Protagonist share promising phase 3 results for icotrokinra in plaque psoriasis

    More than 125 million people globally are estimated to be living with the skin disorder

    - PMLiVE

    Dermavant reports positive long-term results for Vtama cream in atopic dermatitis

    More than 26 million people in the US are affected by the inflammatory skin condition

    - PMLiVE

    Johnson & Johnson’s Tremfya shows promise in ‘special site’ plaque psoriasis

    The immune-mediated disease affects more than 125 million people worldwide

    - PMLiVE

    Bristol Myers Squibb announces positive data for Sotyktu in moderate-to-severe psoriasis

    At least 100 million people worldwide are affected by the immune-mediated disease

    - PMLiVE

    Eli Lilly/Almirall share positive long-term results for Ebglyss in atopic dermatitis

    The inflammatory skin condition occurs in approximately 7.3% of adults in the US

    - PMLiVE

    Almirall announces NICE recommendation for Ebglyss in atopic dermatitis

    The inflammatory skin condition affects about 5.2 million adults and 2.5 million children in the UK

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links